- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01400737
Oral Ibuprofen Prophylaxis for Patent Ductus Arterioses in Very Extremely Low Birth Weight Infants (OIP)
July 21, 2011 updated by: Zekai Tahir Burak Women's Health Research and Education Hospital
Patent ductus arterioses (PDA) is a major morbidity in preterm infants, especially in extremely premature infants less than 28 weeks.
The clinical signs and symptoms of PDA in preterm infants are non specific and insensitive for making an early diagnosis of significant ductal shunting.
Functional echocardiography is emerging as a new valuable bedside tool for early diagnosis of hemodynamically significant ductus, even though there are no universally accepted criteria for grading the hemodynamic significance.
Echocardiography has also been used for early targeted treatment of ductus arterioses, though the long term benefits of such strategy are debatable.
The biomarkers like BNP and N- terminal pro-BNP are currently under research as diagnostic marker of PDA.
The primary mode of treatment for PDA is pharmacological closure using cyclo-oxygenase inhibitors with closure rate of 70-80%.
Oral ibuprofen is emerging as a better alternative especially in Indian scenario where parenteral preparations of indomethacin are unavailable and side effects are comparatively lesser.
Though pharmacological closure of PDA is an established treatment modality, there is still lack of evidence for long term benefits of such therapy as well as there is some evidence for the possible adverse effects like increased ROP and BPD rates, especially if treated prophylactically.The aim of this study is to investigate the effect of oral ibuprofen prophylaxis administrated on the first 24 hours of life and the following two days on hemodynamically significant patent ductus arterioses and its long term effects such as ROP and BPD.
Study Overview
Status
Unknown
Intervention / Treatment
Detailed Description
Patent ductus arterioses (PDA) is a major morbidity encountered in preterm neonates, especially in babies less than 28 weeks gestation or 1000g.Natural ductal closure is inversely related to gestational age and birth weight.
The incidence ranges from 15% to 37% in newborn babies less than 1750 grams.The presence of PDA has significant effects on myocardial functions as well as systemic and pulmonary blood flow.
Preterm newborns adapt, by increasing the left ventricular contractility, and thereby maintaining the effective systemic blood flow even when the left to right shunts equals 50% of the left ventricular output.
This is mainly accomplished by an increase in stroke volume (SV)rather than heart rate.This increase in stroke volume is primarily due to reduction in afterload and simultaneous increase in left ventricular preload.
An increasing number of biological substances like hormones, enzymes which are markers of cardiac stress, dysfunction or myocardial injury-collectively called biomarkers-are emerging as diagnostic and prognostic markers especially in the setting of heart failure or ischemic injury.
The pharmacological basis for medical therapy is the use of non selective cyclo-oxygenase (COX) inhibitors, which inhibits prostaglandin synthesis and causes ductal constriction.
The two most widely studied and used non selective COX inhibitors are indomethacin and ibuprofen.
The future of pharmacological treatment of PDA could be with the use of nitric oxide inhibitors and prostaglandin receptor antagonists.
Ibuprofen is an effective choice for the treatment of PDA in preterm infants as it has been demonstrated in previous several studies.Since there is a meta-analysis that claims there is no need for further studies about ibuprofen prophylaxis to treat PDA in low birth weight infants we aimed to evaluate the effect of ibuprofen prophylaxis in very extremely low birth weight infants.
One such marker emerging in the diagnosis of hs-PDA is brain natriuretic peptide (BNP).
Natriuretic peptides are hormones, produced either by atria (atrial natriuretic peptide-ANP) or by ventricles (BNP) in response to myocardial stress, secondary to dilatation, hypertrophy or increased wall tension.One of the aims of this study is to investigate the effect of oral prophylactic ibuprofen administration on BNP levels and renal functions.
Study Type
Interventional
Enrollment (Anticipated)
200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: H. Gozde Kanmaz, MD
- Phone Number: 90 505 588 11 89
- Email: gzdekanmaz@yahoo.com
Study Contact Backup
- Name: Omer Erdeve, MD
- Email: omererdeve@yahoo.com
Study Locations
-
-
-
Ankara, Turkey
- Recruiting
- Zekai Tahir Burak Maternity Teaching Hospital
-
Contact:
- H. Gozde Kanmaz, MD
- Phone Number: 90 505 588 11 89
- Email: gzdekanmaz@yahoo.com
-
Contact:
- Omer Erdeve, MD
- Email: omererdeve@yahoo.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
5 months to 6 months (CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- < 28 gestational week and/or < 1000 g birth weight preterm infants written parent consent
Exclusion Criteria:
- major congenital anomalies
- congenital heart diseases
- not having written parent consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ibuprofen
The patients in the control group were given 3 doses of an orange starch suspension as placebo that looked like ibuprofen.
|
The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water.
The first dose was given within the first 24 hours of life.
The second and third doses were given within 24 and 48 hours after the first dose respectively.
The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water.
The first dose was given within the first 24 hours of life.
The second and third doses were given within 24 and 48 hours after the first dose respectively
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the effect of oral ibuprofen to prevent hemodynamically significant PDA (hs-PDA) and from rescue therapy
Time Frame: in first week of life
|
on the 3rd day of life all subjects will be examined by a experienced pediatric cardiologist and echocardiography will performed to investigate hs-PDA
|
in first week of life
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
long term effects of oral ibuprofen prophylaxis in VELBW
Time Frame: corrected 36 weeks or until discharge
|
long term effects such as ROP, BPD,IVH, duration of respiratory support and hospitalization are going to be evaluated.
|
corrected 36 weeks or until discharge
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Gokmen T, Erdeve O, Altug N, Oguz SS, Uras N, Dilmen U. Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus. J Pediatr. 2011 Apr;158(4):549-554.e1. doi: 10.1016/j.jpeds.2010.10.008. Epub 2010 Nov 20. Erratum In: J Pediatr. 2012 Jan;160(1):181.
- Erdeve O, Gokmen T, Altug N, Dilmen U. Oral versus intravenous ibuprofen: which is better in closure of patent ductus arteriosus? Pediatrics. 2009 Apr;123(4):e763. doi: 10.1542/peds.2009-0003. No abstract available.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2011
Primary Completion (Anticipated)
July 1, 2012
Study Completion (Anticipated)
July 1, 2012
Study Registration Dates
First Submitted
July 19, 2011
First Submitted That Met QC Criteria
July 21, 2011
First Posted (Estimate)
July 22, 2011
Study Record Updates
Last Update Posted (Estimate)
July 22, 2011
Last Update Submitted That Met QC Criteria
July 21, 2011
Last Verified
July 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Congenital Abnormalities
- Heart Defects, Congenital
- Cardiovascular Abnormalities
- Body Weight
- Birth Weight
- Ductus Arteriosus, Patent
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Ibuprofen
Other Study ID Numbers
- 2011-09-ibuprofen
- 2011-09 (Other Identifier: Zekai Tahir Burak Maternity Teaching Hospital)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oral Ibuprofen Prophylaxis in Very Low Birth Weight Infants
-
Sakarya UniversityUnknownOral Colostrum Administration in Very Low Birth Weight Premature InfantsTurkey
-
Milton S. Hershey Medical CenterChildren's Miracle NetworkCompletedVery Low Birth Weight InfantsUnited States
-
Zekai Tahir Burak Women's Health Research and Education...CompletedVery Low Birth Weight InfantsTurkey
-
Seoul National University HospitalKangWon National University HospitalCompletedVery Low Birth Weight InfantsKorea, Republic of
-
Zekai Tahir Burak Women's Health Research and Education...UnknownAnticandidal Property of Saccharomyces Boulardii on Very Low Birth Weight InfantsTurkey
-
Seoul National University HospitalSeoul St. Mary's Hospital; CHA UniversityCompleted
-
University of ChicagoTerminatedIntraventricular Hemorrhage | Premature Infants | Very Low Birth Weight InfantsUnited States
-
University of VirginiaThe Gerber FoundationUnknownVery Low Birth Weight InfantsUnited States
-
China Medical University HospitalWithdrawnVery Low Birth Weight InfantsTaiwan
-
Zekai Tahir Burak Women's Health Research and Education...CompletedNecrotizing Enterocolitis | Very Low Birth Weight InfantsTurkey
Clinical Trials on ibuprofen
-
Reckitt Benckiser Healthcare (UK) LimitedPremier Research Group plcCompletedStomatognathic Diseases | Tooth Diseases | Tooth, ImpactedUnited States
-
Reckitt Benckiser Healthcare (UK) LimitedTerminated
-
Reckitt Benckiser Healthcare (UK) LimitedSimbec ResearchCompletedHealthy Volunteer Study
-
Overseas Pharmaceuticals, Ltd.Virginia Contract Research Organization Co., Ltd.Terminated
-
Fundacion para la Investigacion Biomedica del Hospital...CompletedPatent Ductus ArteriosusSpain
-
Darnitsa Pharmaceutical CompanyACDIMA BiocenterCompletedHealthy Subjects | BioequivalenceJordan
-
Pierre Fabre MedicamentCompleted
-
Indonesia UniversityCompleted
-
SocraTec R&D GmbHSocraMetrics GmbHCompleted